gefitinib has been researched along with bromodeoxyuridine in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (bromodeoxyuridine) | Trials (bromodeoxyuridine) | Recent Studies (post-2010) (bromodeoxyuridine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 13,164 | 71 | 1,816 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, J; Kang, S; Kim, JH; Ko, SG; Kwon, YY; Moon, JH | 1 |
1 other study(ies) available for gefitinib and bromodeoxyuridine
| Article | Year |
|---|---|
SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition.
Topics: Animals; Apoptosis; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Ki-67 Antigen; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Necrosis Factor-alpha; Vimentin | 2022 |